IMM 3.13% 31.0¢ immutep limited

Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-81

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,637 Posts.
    lightbulb Created with Sketch. 382

    iscusi
    No wonder they keep mentioning ”trial design” and “discussions with regulators” re phase3. A picture is starting to emerge and I like it.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.